Payment overview · 2025
General Payments
$322.36
14 reported records · 6 companies
Healthcare provider profile · identity verified
Paul D Sain, MD
Allopathic & Osteopathic Physicians|Family Medicine · FAYETTEVILLE, TN · NPI 1023086675
Verified facts
What the public records show
CMS Open Payments records show Paul D Sain, MD received $322.36 in general payments during 2025 across 14 reported records.
Astellas Pharma US Inc accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $118.90 | 36.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.68 | 20.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.42 | 18.4% | 3 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $39.58 | 12.3% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $25.02 | 7.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.76 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $322.36 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $118.90 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $59.42 | 3 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 110 |
| Gabapentin | Gabapentin | 381 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 355 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 332 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 85 |
| Losartan Potassium | Losartan Potassium | 254 | 69 |
| Levothyroxine Sodium | Levothyroxine Sodium | 237 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 224 | 50 |
| Potassium Chloride | Potassium Chloride | 222 | 64 |
| Alprazolam | Alprazolam | 216 | 29 |
| Lisinopril | Lisinopril | 209 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 179 | 50 |
| Furosemide | Furosemide | 166 | 50 |
| Trazodone Hcl | Trazodone Hcl | 154 | 33 |
| Pregabalin | Pregabalin | 153 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 145 | 33 |
| Allopurinol | Allopurinol | 143 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 32 |
| Omeprazole | Omeprazole | 142 | 38 |
| Meloxicam | Meloxicam | 138 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 136 | 29 |
| Metformin Hcl | Metformin Hcl | 135 | 42 |
| Jardiance | Empagliflozin | 117 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 37 |
| Carvedilol | Carvedilol | 111 | 31 |
| Lorazepam | Lorazepam | 109 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 37 |
| Eliquis | Apixaban | 106 | 18 |
| Famotidine | Famotidine | 102 | 31 |
| Montelukast Sodium | Montelukast Sodium | 102 | 26 |
| Baclofen | Baclofen | 99 | 13 |
| Warfarin Sodium | Warfarin Sodium | 99 | 16 |
| Ozempic | Semaglutide | 97 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 95 | 28 |
| Simvastatin | Simvastatin | 90 | 26 |
| Oxycodone Hcl | Oxycodone Hcl | 82 | suppressed |
| Glimepiride | Glimepiride | 77 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 72 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 18 |
| Promethazine Hcl | Promethazine Hcl | 67 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 66 | suppressed |
| Prednisone | Prednisone | 65 | 45 |
| Sertraline Hcl | Sertraline Hcl | 65 | 18 |
| Sucralfate | Sucralfate | 65 | 14 |
| Celecoxib | Celecoxib | 64 | 13 |
| Buspirone Hcl | Buspirone Hcl | 63 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 16 |
| Alendronate Sodium | Alendronate Sodium | 58 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 50 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Diazepam | Diazepam | 57 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 19 |
| Divalproex Sodium | Divalproex Sodium | 54 | suppressed |
| Spironolactone | Spironolactone | 53 | 17 |
| Cephalexin | Cephalexin | 52 | 42 |
| Torsemide | Torsemide | 51 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 11 |
| Methocarbamol | Methocarbamol | 50 | suppressed |
| Linzess | Linaclotide | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 13 |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Januvia | Sitagliptin Phosphate | 47 | suppressed |
| Atenolol | Atenolol | 46 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 39 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 12 |
| Fluconazole | Fluconazole | 37 | 21 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Xtampza Er | Oxycodone Myristate | 36 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 33 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 23 |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 26 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Valsartan | Valsartan | 25 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 20 |
| Estradiol | Estradiol | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Novolin R | Insulin Regular, Human | 22 | suppressed |
| Nystatin | Nystatin | 22 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Azithromycin | Azithromycin | 16 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 16 | suppressed |
| Vraylar | Cariprazine Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Nabumetone | Nabumetone | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Minoxidil | Minoxidil | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Quinine Sulfate | Quinine Sulfate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $322.36 · 14 records | Astellas Pharma US Inc | ABRYSVO, COMIRNATY, Cologuard Collection Kit, Heplisav-B, NEXPLANON, Ozempic, PREVNAR 20, Rybelsus, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error